small molecule

LIVMARLI

MARALIXIBAT CHLORIDE

Loss of exclusivityFebruary 2040latest FDA-listed patent expiry

CompanyMirum Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	LIVMARLI
Active ingredient	MARALIXIBAT CHLORIDE
Strength	EQ 9.5MG BASE/ML
Dosage form	SOLUTION
Route	ORAL
Modality	Small molecule
FDA approval	September 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
12599602	February 2040	use U-3290
11918578	February 2040	use U-3974
11229647	February 2040	use U-3290
11497745	February 2040	use U-3290
10512657	October 2032	use U-3850
11229661	October 2032	use U-3850
11376251	October 2032	use U-3974
11260053	May 2031	use U-3290

Regulatory exclusivity

Code	Expires
ODE-471	March 2031
ODE-429	March 2030
ODE-379	September 2028
I-938	March 2027
NCE	September 2026
NPP	March 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Mirum Pharmaceuticals